Such drugs, which initially were developed to help control blood glucose levels in people with type 2 diabetes, have a variety of metabolic effects, such as promoting the secretion of insulin, suppressing the release of glucagon, delaying the process of stomach emptying, and increasing feelings of satiety [83,84]. Here, INS is linked to type 2 diabetes mellitus.